MEI Pharma Inc. | Balance Sheet

Fiscal year is July-June. All values USD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
48,793.00
63,779.00
45,918.00
53,565.00
102,743.00
Other Current Assets
497.00
502.00
831.00
1,758.00
1,586.00
Total Current Assets
49,290.00
64,281.00
46,749.00
55,323.00
104,329.00
Net Property, Plant & Equipment
83.00
68.00
49.00
50.00
32.00
Intangible Assets
435.00
401.00
366.00
331.00
296.00
Total Assets
49,808.00
64,750.00
47,164.00
55,704.00
104,657.00
Accounts Payable
1,708.00
863.00
-
585.00
3,643.00
Other Current Liabilities
2,908.00
4,096.00
5,512.00
4,281.00
4,242.00
Total Current Liabilities
4,616.00
4,959.00
5,512.00
4,866.00
7,885.00
Other Liabilities
-
-
-
-
46,313.00
Total Liabilities
4,616.00
4,959.00
5,512.00
4,866.00
54,198.00
Common Equity (Total)
45,192.00
59,791.00
41,652.00
50,838.00
50,459.00
Total Shareholders' Equity
45,192.00
59,791.00
41,652.00
50,838.00
50,459.00
Total Equity
45,192.00
59,791.00
41,652.00
50,838.00
50,459.00
Liabilities & Shareholders' Equity
49,808.00
64,750.00
47,164.00
55,704.00
104,657.00

About MEI Pharma

View Profile
Address
3611 Valley Centre Drive
San Diego California 92130
United States
Employees -
Website http://www.meipharma.com
Updated 07/08/2019
MEI Pharma, Inc. engages in the clinical development of novel therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, a highly selective, oral PI3K delta inhibitor; voruciclib, an oral, selective CDK inhibitor; and ME-344, a novel mitochondrial inhibitor.